CEO of biOasis Technologies Gives Update to Shareholders

Pharmaceutical Investing

The CEO of biOasis Technologies issued a message to shareholders for the advancement of the Transcend Platform and the company’s in-house programs.

The CEO of biOasis Technologies (OTCQB:BIOAF; TSXV:BTI) issued a message to shareholders for the advancement of the Transcend Platform and the company’s in-house programs.
As quoted in the press release:

To the Shareholders of biOasis Technologies Inc.:
As the new CEO of biOasis, I am delighted to send my first message to shareholders, especially at a time when there is such excitement in the neurosciences. Scientists are beginning to understand the surreal complexity of the central nervous system (CNS), how to explore further into its mysteries, to understand its workings, diagnose its diseases, and how to accurately monitor the progress of CNS diseases and the efficacy of the drugs that treat them.
I and my many friends and colleagues in the industry are moving ahead on many fronts. Celgene and Vertex have recently moved into the CNS arena under the guidance of two exceptional R&D leaders. In 2014 the Nobel Prize in Physiology or Medicine was awarded to a team that made breakthrough discoveries on spatial memory, discoveries that have informed my own work.
Several significant breakthroughs were made in the last year. The most exciting for me was with Alzheimer’s disease. Biogen demonstrated their aducanumab could slow the progression of Alzheimer’s disease in mild-to-moderate patients. This truly was a first and shows that when you prioritize science, you can yield truly astounding results.

Click here to read the full press release.

Source: www.marketwired.com

The Conversation (0)
×